Stockreport
Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings [Seeking Alpha]
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
VRTX's CF franchise continues to grow via ALYFTREK's launch, geographic expansion, and penetration into younger and rare mutation populations, supporting robust revenue. New products JOURNAVX and CASGEVY are gaining traction, and the renal pipeline—especially povetacicept—could become a second franchise with multi-billion-dollar potential. I maintain a conviction rating of 4/5 for VRTX, actively adding below $443.07 ahead of Q1 earnings and multiple 2026–2027 catalysts. Looking for a portfolio of ideas like this one? Members of Compounding Healthcare get exclusive access to our subscriber-only portfolios. Learn More » jurgenfr/iStock via Getty Images It has been over four months since I last covered Vertex Pharmaceuticals ( VRTX ), where I discussed how the company was still the unquestionable leader in cystic fibrosis (CF) but was working to diversify into pain, kidney disease, and More on my IG service Thank you for reading my research on Seeking Alpha. If you want to
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | VRTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
VRTX alerts
VRTX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
NEWS
NEWS
- Jim Cramer on Vertex Pharmaceuticals: “I Wish I Had Bought It for the Charitable Trust a Long Time Ago” [Yahoo! Finance][Yahoo! Finance]
- Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now? [Yahoo! Finance][Yahoo! Finance]
- 2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term [Globe and Mail, The (Toronto, Canada)][Globe and Mail, The]
- 2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term [Yahoo! Finance][Yahoo! Finance]
- How an unsolved medical mystery became a life-saving breakthrough [USA TODAY][USA TODAY]
- More
VRTX
SEC Filings
SEC Filings
- 4/17/26 - Form 4
- 4/17/26 - Form 4
- 4/17/26 - Form 4
- VRTX's page on the SEC website
- More